Indication · Otolaryngology (ENT)
Head and neck cancer
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
54
Cleared or approved since 2000
PMA and De Novo
2
Higher-risk or first-of-kind devices
Breakthrough devices
1
Authorized through June 30, 2026
Recruiting device trials
42
287 device trials in all
Breakthrough-designated devices
- MuReva OMMureva Phototherapy, Inc. · 2025
Devices
54 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- MuReva OM
Mureva Phototherapy, Inc. · De Novo · Intraoral Phototherapy Device · newest 2025
53 more devices with a free account
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
Oslo University HospitalAcademic, hospital or other
NCT04337853 · 13 participants · Start Mar 9, 2018 · Primary completion Dec 4, 2018
Device: Intraoral stent · For: Tongue Cancer
Sites: Oslo, Norway
286 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Material, Polytetrafluoroethylene Vitreous Carbon, For Maxillofacial Reconstruction (KKY)14
- System, Vocal Cord Medialization (MIX)14
- Diagnostic Light, Soft Tissue Detector (NXV)12
- Prosthesis, Laryngeal (Taub) (EWL)9
- Prosthesis, Larynx (Stents And Keels) (FWN)2
- Device To Detect Or Measure Nucleic Acid From Viruses Associated With Head And Neck Cancers (OJY)1
- Sleeve, Head And Neck, Compressible (PPS)1
- Intraoral Phototherapy Device (SGQ)1
Research
- Device studies on head and neck cancer across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.